MONTREAL, CANADA – August 2nd, 2016 -S.I.F.I- Società Industria Farmaceutica Italiana S.p.A. (“SIFI”), a prominent Italian Eye Care company, and Knight Therapeutics Inc. (TSX: GUD) (“Knight”), a leading Canadian specialty pharmaceutical company, announced today that they have entered into an agreement whereby Knight received the exclusive rights to commercialize NETILDEX™ in Canada. NETILDEX™ is a fixed combination of netilmicin and dexamethasone for the treatment of ocular inflammation of the anterior segment of the eye, in presence or at risk of bacterial infection. Under the terms of this agreement, Knight will also handle all ongoing regulatory and commercial activities for NETILDEX™ in Canada. Destum Partners acted as the advisor for SIFI on this agreement.
